1. Radium-223 voor gemetastaseerd castratieresistent prostaatcarcinoom: stand van zaken en toekomstperspectief.
- Author
-
Wyndaele, Dirk N. J.
- Abstract
In recent years, the armamentarium of life-prolonging systemic agents for metastatic castration-resistant prostaste cancer (mCRPC) has been expanded with radium-223 (Ra-223), abirateron, enzalutamide and cabazitaxel. Since 2013, Ra-223 is approved in the European Union as a Targeted alpha Therapy (TaT) for the treatment of patients with mCRPC and symptomatic bone metastases. Recently issued recommendations by a European expert group for the optimal usage of all life-prolonging treatment options for mCRPC position Ra-223 as a relevant option for second- and third-line treatment after androgen receptor inhibitors and/or docetaxel. This review paper summarizes these recommendations. It also describes real-world experience with Ra-223 accumulated in recent years and provides outlines of the most important recently completed or ongoing clinical trials of Ra-223 in combination with docetaxel, androgen receptor inhibitors, immunomodulatory anticancer agents or PARP inhibitors. The possible future application of PSMA-directed radioligand therapy in prostate cancer is briefly outlined. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF